Patricia L. Kropf, MD, discusses a combination of decitabine and arsenic trioxide as a replacement for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who cannot withstand induction chemotherapy.
Patricia L. Kropf, MD
Articles by Patricia L. Kropf, MD
Latest Updated Articles
Dr. Patricia L. Kropf on Decitabine and Arsenic Trioxide in AML and MDSPublished: December 10th 2015 | Updated: